Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.
Phase: PHASE2
Conditions: Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Sponsor: McMaster University

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 1 
 
 
 
CLINICAL TRIAL PROTOCOL 
 
 
 
Protocol Title: 
Benralizumab regulates atopic dermatitis through effects 
on eosinophils, basophils and innate lymphoid type 2 
cells. 
 
Principal Investigator: 
 
Co-Investigators: 
Gail Gauvreau PhD 
 
 
Hermenio Lima MD, PhD 
Roma Sehmi PhD 
Mark Inman MD, PhD 
 
 
Study Site: 
McMaster University,  
Department of Medicine,  
1200 Main St West, 
Hamilton, Ontario,  
Canada L8N 3Z5 
 
Protocol Number: 
 
ESR-16-12430 
Protocol Version: 
8.1 – 27MAY2019 
Short Title: 
Effect of benralizumab in atopic dermatitis 
 
 
 
 
 
 
 
 
 
 
 
The study will be performed in accordance with the ethical principles of the Declaration of 
Helsinki, and consistent with International Conference on Harmonization (ICH)/Good Clinical 
Practice (GCP) and applicable regulatory requirements. Approval will be obtained from the local 
ethics committee, and all patients provided written and informed consent. 
 
 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 2 
 
Table of Contents 
Background ..................................................................................................................................... 4 
Hypothesis....................................................................................................................................... 5 
Study design .................................................................................................................................... 5 
Screening..................................................................................................................................... 5 
Effect of treatment on clinical disease ........................................................................................ 5 
Effect of treatment on allergen-induced responses ..................................................................... 5 
Follow-up .................................................................................................................................... 6 
Figure 1 - Study flow chart. ........................................................................................................ 6 
Duration of the study ...................................................................................................................... 6 
Study period .................................................................................................................................... 7 
Blinding........................................................................................................................................... 7 
Study Objectives ............................................................................................................................. 7 
Primary Objective: ...................................................................................................................... 7 
Secondary Objectives: ................................................................................................................ 7 
Exploratory Objectives: .............................................................................................................. 7 
Selection of Study Population ......................................................................................................... 8 
Inclusion Criteria ............................................................................................................................ 8 
Exclusion Criteria ........................................................................................................................... 9 
Investigational product.................................................................................................................. 12 
Investigational product administration ......................................................................................... 12 
Efficacy Endpoints ........................................................................................................................ 13 
Primary endpoint ....................................................................................................................... 13 
Secondary endpoints ................................................................................................................. 13 
Exploratory endpoints ............................................................................................................... 13 
Safety Variables ............................................................................................................................ 13 
Adverse Events ......................................................................................................................... 14 
Serious Adverse Events ............................................................................................................ 14 
Safety Reporting ........................................................................................................................... 16 
Procedures ..................................................................................................................................... 16 
Skin Prick Test .......................................................................................................................... 16 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 3 
 
Intradermal Allergen Challenge ................................................................................................ 17 
Skin Sampling ........................................................................................................................... 17 
Figure 2 – Site of skin biopsies ................................................................................................. 18 
Blood Sampling ........................................................................................................................ 18 
Eczema Area and Severity Index .............................................................................................. 19 
Statistical methods ........................................................................................................................ 19 
Ethics............................................................................................................................................. 20 
Research Ethics Board .............................................................................................................. 20 
Ethical Conduct of the Study .................................................................................................... 20 
Subject Information and Consent.............................................................................................. 20 
Study Feasibility ........................................................................................................................... 21 
Clinical trial experience ............................................................................................................ 21 
Patient recruitment .................................................................................................................... 21 
Outcome measurements ............................................................................................................ 21 
Study Budget ................................................................................................................................. 22 
References ..................................................................................................................................... 23 
 
 
 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 4 
 
Background 
Atopic dermatitis (AD) is a common skin disease that is characterized by chronic, 
relapsing skin inflammation and eczematous, itchy lesions (Beiber, 2008). The prevalence of AD 
has increased over the past few decades, with 15-30% of children and 2-10% of adults being 
affected (Williams & Flohr, 2006). The pathogenesis of AD is as a result of a complex 
interaction between the epidermal barrier, the immune system and pruritus, with each factor 
contributing to disease initiation and progression (Kabashima, 2013). As the epidermal barrier 
breaks down in skin of AD patients, allergens are exposed to the underlying antigen presenting 
cells (APC’s). Primed APC’s migrate to local lymph nodes and activate naive T cells to Th2 
cells. Th2 cells then traffic to the AD lesion and promote eosinophilic inflammation through 
release of Th2 cytokines (IL-4, IL-13, IL-25) and TSLP (Peng & Novak, 2015). Immune cells 
such as eosinophils, mast cells, basophils, innate lymphoid cells (IL-C2s) and dendritic cells 
infiltrate into the AD lesion, while circulating Th2 cells cause an increase in IgE and eosinophils 
in serum (Leung et al, 2004). 
Interleukin-5 (IL-5) is a key cytokine involved in the differentiation and maturation of 
eosinophils from hematopoietic stem cells in the bone marrow, their mobilization and migration 
from the bone marrow to the blood, and their activation and survival in tissue (Blanchard and 
Rothenberg, 2009).  The receptor for IL-5 (IL-5Rα) is expressed on eosinophils and basophils, 
but may also be expressed on other recently identified cells, such as innate lymphoid type 2 cells 
(ILC2).   
There is evidence that in chronic allergic inflammatory diseases, eosinophilia may arise as a 
result of (i) the recruitment of mature cells from the periphery in response to locally elaborated 
chemoattractants such as eotaxin (Wardlaw et al., 1999) and/or (ii) the localized maturation of 
eosinophil lineage-committed progenitors, termed “in situ differentiation” in the presence of 
locally elaborated cytokines namely IL-5 (Sehmi et al., 2000; Sehmi et al., 2016). It is now 
apparent that type 2 innate lymphoid cells are an important source of IL-5 in mucosal tissue 
promoting eosinophilic inflammation including the skin in atopic dermatitis (Kim et al., 2013; 
Bonefeld et al., 2016). The aim of the current study is to target the local eosinophilopoietic 
process by interfering with the IL-5/IL-5Rα signaling axis. Our previous and ongoing studies 
show that eosinophils, basophils, eosinophil progenitor cells and innate lymphoid type 2 cells 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 5 
 
express IL-5Rα and may be a target population for benralizumab, a humanized afucosylated 
antibody directed against IL-5Rα subunit.   
Hypothesis 
In atopic dermatitis, local IL-5 driven eosinophilopoietic processes contribute to development of 
tissue eosinophilia. Targeting the IL-5/ IL-5Rα axis will attenuate eosinophilic inflammation in 
the skin.  
Study design 
This randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect 
of 3 doses of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) every 4 
weeks to patients with moderate-to-severe atopic dermatitis, on the severity of atopic dermatitis, 
and the cellular inflammation of skin lesions in these patients.  
Screening and Baseline 
During a screening period (Days -1 to 0), patients with moderate-to-severe atopic dermatitis who 
develop late phase cutaneous response following intradermal allergen challenge, will be recruited 
for the study. 
Effect of treatment on clinical disease 
Skin lesions will be graded using validated scales before the start of treatment, and throughout 
the study to assess the effect of benralizumab on changes to the severity of disease. Biopsies 
from skin lesions and samples of peripheral blood will be examined for levels of cells that 
express IL-5Rα subunit including eosinophils, basophils, eosinophil progenitor cells, and innate 
lymphoid type 2 cells using flow cytometry. In addition, methylcellulose colony forming assay 
will be used to enumerate the IL-5 driven clonogenic potential of progenitor cell populations 
within the blood.  
Effect of treatment on allergen-induced responses 
An intradermal allergen challenge will be conducted 1 week after the last dose of study drug to 
determine the effect of benralizumab on allergen-induced responses in skin. The size of the 
resulting skin wheal will be measured at 24h post-challenge. Biopsies of the skin wheal will be 
obtained for measurements of eosinophils and basophils per mm2 tissue using standard 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 6 
 
histochemical and immuno-histochemical stains. Additional biopsies of the skin wheal will be 
collected to measure the frequency of eosinophils, basophils, eosinophil progenitor cells, and 
innate lymphoid type 2 cells by flow cytometry.  
Follow-up 
Patients will return for a safety follow-up visit on study Day 140 (week 20), which is 12 weeks 
after the last dose/11 weeks after the last study procedure.  
                      
  
Figure 1 - Study flow chart.  
Randomized double-blind,placebo-controlled, parallel-group prospective study. Patients with a history of atopic 
dermatitis will enter a screening period to assess responses to intradermal allergen challenge. Those developing a 
late cutaneous response 24 hours later will have the size of the wheal/flare measured and a punch biopsy obtained 
from the challenge site for measurement of eosinophils and basophils. Patients will then be randomized 1:1 to 
benralizumab (30 mg SC monthly) or placebo, with dosing at days 0, 28 and 56. Blood and a sample of a skin lesion 
will be collected on Day 0 before dosing. A skin lesion will be collected at Day 28 and blood will be collected again 
65 days after the first dose, for assessments of eosinophils, basophils and other cells including eosinophil 
progenitors, ILC2s, hemopoietic progenitor cells and CD4+ T cells. On Day 64 an intradermal allergen challenge 
will be conducted and on Day 65 the size of the wheal/flare will be measured and a punch biopsy will be obtained 
from the challenge site for a measurement of eosinophils and basophils. Skin lesions will be assessed clinically 
before dosing and throughout the study using the EASI score. A safety follow up visit will take place at week 20, 
which is140 days after the first dose (12 weeks after the last dose). Each visit has a +/- 3 day window with the 
exception of Day 0 and Day 65 which must take place exactly 1 day after Day -1 and Day 64, respectively. 
Duration of the study 
The total length of a patient’s participation in the trial is up to 25 weeks; 
• up to 4 weeks screening period 
• 8 weeks treatment period 
• 1 week post-treatment period 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 7 
 
• 12 weeks follow-up 
Study period 
Estimated date of first subject enrolled Q4 2017 
Estimated date of last subject completed Q2 2019 
Blinding 
This study will be a double-blind study, using a placebo.  The placebo will have an appearance 
identical to that of drug.  The staff who administers the treatment, any study staff involved in 
subject evaluations, and the subjects, will remain blinded to treatment assignment for the 
duration of the study.  
Study Objectives 
Primary Objective: 
The primary objective is to evaluate the effect of benralizumab on the allergen-induced number 
of eosinophils in the skin assessed by histological examination on Day 65, at 24h post-
intradermal allergen challenge, compared to placebo. Intradermal saline challenge will be used as 
a control. 
Secondary Objectives: 
The secondary objectives are to evaluate the effect of benralizumab on (i) the allergen-induced 
number of basophils in the skin, as assessed by immuno-histochemical staining of a biopsy of the 
skin wheal collected on Day 65, at 24h post-intradermal allergen challenge, compared to 
placebo, (ii) the allergen-induced late phase cutaneous response by measuring the skin wheal on 
Day 65, at 24h post-intradermal allergen challenge, compared to placebo, and (iii)  on disease 
severity at 65 days post-treatment, by assessing skin lesions using the Eczema Area and Severity 
Index (EASI) score, compared to placebo. 
Exploratory Objectives: 
The exploratory objectives are to evaluate the effect of benralizumab on the number of 
eosinophils, basophils, eosinophil progenitor cells and innate lymphoid type 2 cells, CD4+ T 
cells and hemopoietic cells in skin lesions on Day 28 post-treatment, compared to placebo. 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 8 
 
Comparisons of local versus systemic drug-induced changes will be made by making similar 
cellular assessments in the blood on Day 65. In addition, we will prepare methylcellulose cell 
cultures from samples of Day 65 peripheral blood to enumerate the out-growth potential of the 
circulating eosinophil/basophil progenitor cell population.     
Selection of Study Population 
Men and women, 18 to 65 years of age, with moderate-to-severe atopic dermatitis, whose disease 
cannot be adequately controlled with, and agree to withhold, topical/oral anti-inflammatory 
medications. The total enrollment for the study will be sufficient to result in 20 evaluable 
subjects. Any patients dropping out of the study prior to primary outcome assessment will be 
replaced. 
Inclusion Criteria 
The following inclusion criteria must be met for to enter the screening phase of the study: 
 
1. 
Male and female patients 18 through 65 years of age.  
2. 
Women of childbearing potential (WOCBP) must not be actively seeking pregnancy, and 
must use an effective form of birth control (confirmed by the Investigator). Effective forms of 
birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female 
sterilization by tubal occlusion, any effective IUD intrauterine device/IUS levonorgestrel 
Intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or 
Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from 
enrolment, throughout the study duration and within 16 weeks after last dose of IP. They must 
demonstrate a negative serum pregnancy test at screening and demonstrate a negative urine 
pregnancy test immediately before each dose of study drug or placebo. Women not of 
childbearing potential are defined as women who are either permanently sterilized 
(hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.  
Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to 
the planned date of randomization without an alternative medical cause.  The following age-
specific requirements apply: 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 9 
 
• 
Women <50 years old would be considered postmenopausal if they have been 
amenorrheic for 12 months or more following cessation of exogenous hormonal 
treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range. 
• 
Women ≥50 years old would be considered postmenopausal if they have been 
amenorrheic for 12 months or more following cessation of all exogenous hormonal 
treatment. 
3. 
All male patients who are sexually active must agree to use an acceptable method of 
contraception (condom with or without spermicide, vasectomy) from the first dose of IP until 16 
weeks after their last dose. 
4. 
General good health 
5. 
Moderate to severe atopic dermatitis 
6. 
Able to understand and give written informed consent and has signed a written informed 
consent form approved by the investigator’s REB 
 
The following inclusion criteria must be met for entry into the dosing phase of the study: 
 
1. 
Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen) 
2. 
Positive late cutaneous response to intradermal allergen challenge  
Exclusion Criteria 
Patients should not enter the study if any of the following exclusion criteria are fulfilled: 
1. History of anaphylaxis to any biologic therapy or vaccine 
2. History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, 
or light headedness, as judged by the investigator 
3. Any history or symptoms of clinically significant cardiovascular disease, particularly 
coronary artery disease, arrhythmias, hypertension, or congestive heart failure 
4. Any history or symptoms of clinically significant neurologic disease, including transient 
ischemic attack (TIA), stroke, seizure disorder, or behavioral disturbances 
5. Any history or symptoms of clinically significant autoimmune disease 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 10 
 
6. Any history of clinically significant haematologic abnormality, including coagulopathy or 
any history of chronic treatment with anticoagulants (e.g. warfarin, etc) or antiplatelet 
agent (e.g, aspirin, etc) 
7. Clinically significant abnormalities in laboratory test results at enrolment and during the 
screening period (including complete blood count, coagulation, chemistry panel and 
urinalysis) unless judged not significant by the investigator.  
8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times 
the upper limit of normal (ULN) confirmed during screening period 
9. Being pregnant or lactating or have positive serum pregnancy test at enrolment or 
positive urine pregnancy test during the study 
10. Concomitant disease or condition which could interfere with the conduct of the study, or 
for which the treatment might interfere with the conduct of the study, or which would, in 
the opinion of the investigator, pose an unacceptable risk to the patient in this study, 
including, but not limited to, cancer, alcoholism, drug dependency or abuse, or 
psychiatric disease 
11. Severe concomitant illness(es) that, in the investigator’s judgment, would adversely 
affect the patient’s participation in the study  
12. Presence of skin comorbidities that may interfere with study assessments  
13. History of cancer: Patients who have had basal cell carcinoma, localized squamous cell 
carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the 
subject is in remission and curative therapy was completed at least 12 months prior to the 
date informed consent. Patients who have had other malignancies are eligible provided 
that the subject is in remission and curative therapy was completed at least 5 years prior 
to the date of informed consent. 
14. Patient who has a scheduled in-patient surgery or hospitalization during the study. 
15. History of Guillain-Barré syndrome 
16. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed 
consent is obtained that has not been treated with, or has failed to respond to standard of 
care therapy 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 11 
 
17. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive 
medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination 
without history of hepatitis B are allowed to enrol 
18. A history of known immunodeficiency disorder including a positive human 
immunodeficiency virus (HIV) test 
19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed 
consent is obtained  
20. Receipt of any marketed (eg omalizumab) or investigational biologic within 4 months or 
5 half-lives prior to randomization is obtained, whichever is longer 
21. Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known), 
whichever is longer, before the baseline visit  
22. Any allergen immunotherapy within 4 months prior to or throughout the study. 
23. Having used any of the following treatments within 4 weeks before the Day -2 baseline 
visit, or any condition that, in the opinion of the investigator, is likely to require such 
treatment(s) during study:  
a. Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, 
cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, 
azathioprine, methotrexate, etc.)  
b. Phototherapy for AD  
24. Any cell-depleting agents including but not limited to rituximab: within 6 months before 
the baseline visit, or until lymphocyte count returns to normal, whichever is longer  
25. Initiation of treatment of AD with prescription moisturizers or moisturizers containing 
additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products 
during the screening period (patients may continue using stable doses of such 
moisturizers if initiated before the screening visit)  
26. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the 
baseline visit  
27. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or 
superficial skin infections within 1 week before the baseline visit. NOTE: patients may be 
rescreened after infection resolves  

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 12 
 
28. Known or suspected history of immunosuppression, including history of invasive 
opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, 
pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, 
recurrent, or prolonged infections, per investigator judgment  
29. Planned or anticipated major surgical procedure during the patient’s participation in this 
study  
30. Receipt of live attenuated vaccines 30 days prior to the date of randomization. Receipt of 
inactive/killed vaccinations (eg, inactive influenza) are allowed provided they are not 
administered within 1 week before/after any IP administration. 
31. Patient is a member of the investigational team or his/her immediate family 
32. Pregnant woman 
33. Previously received benralizumab (MEDI-563) 
Investigational product 
Benralizumab 30 mg or placebo solution for injection will be administered SC every month, for 
3 doses. Subjects will be randomized in a 1:1 ratio. The IP will be administered at the study 
centre on treatment visits on study days 0, 28 and 56 (± 3 days). The placebo will have an 
appearance identical to that of drug.  Those administering treatment, any study staff involved in 
subject evaluations, and the subjects, will remain blinded to treatment assignment for the 
duration of the study.  
Investigational product administration 
The IP will be administered by a study physician.  For WOCBP urine pregnancy test will be 
done; IP will be administered only when the result of the test is negative. The site of injection of 
the IP is rotated such that the patient receives IP at a different anatomical site at each treatment 
visit. The injection site will be recorded at each treatment visit. After IP administration the 
subject should be observed for a minimum of 2 hours for the appearance of any acute drug 
reactions. 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 13 
 
Efficacy Endpoints 
Primary endpoint 
1. The number of eosinophils per millimetre squared of skin, measured 24 hours post 
intradermal allergen challenge, 65 days after the first dose. The number of eosinophils in 
the skin will be assessed by histological examination of a punch skin biopsy obtained 
from the site of the intradermal allergen challenge.  
Secondary endpoints 
1. The number of basophils per millimetre squared of skin, measured 24 hours post 
intradermal allergen challenge, after 65 days of dosing. The number of basophils in the 
skin will be assessed by immunohistochemistry of a punch skin biopsy obtained from the 
site of the intradermal allergen challenge, using a commercial antibody specific for 
basophils.  
2. The size of the late cutaneous response, measured 24 hours post intradermal allergen 
challenge, 65 days after the first dose. The late cutaneous response will be calculated 
using the length and width of the wheal and flare response to a standardized amount of 
allergen extract.  
3. Eczema Area and Severity Index (EASI) score. 
Exploratory endpoints 
1. The number of eosinophils, basophils, eosinophil progenitors, ILC2s, CD4+ T cells and 
hemopoietic cells in skin lesions after 28 days of dosing. The number of cells in skin 
lesions will be assessed by flow cytometry following digestion of the biopsy and staining 
with a validated panel of antibodies. 
Safety Endpoints 
Blood and urine will be evaluated during screening for study eligibility, and at follow up to 
determine safety. 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 14 
 
Safety Variables 
Adverse Events 
An AE is defined as any untoward medical occurrence in a clinical investigation subject who 
receives a pharmaceutical product at any dose, whether or not there is a causal relationship with 
the investigational treatment.  An AE could therefore be any unfavorable or unintended sign 
(including abnormal laboratory findings), symptom, or disease temporally associated with the 
use of a medicinal product, whether or not considered related to the medicinal product.  This 
definition includes intercurrent illnesses or injuries and exacerbation of pre-existing conditions.  
An unexpected AE is an AE not identified in nature, severity, or frequency in the current 
Investigator Drug Brochure. 
The investigator will rate the intensity of AEs according to the following categories. 
• Mild = symptoms or signs present; no limitation of activities; no medical intervention 
required. 
• Moderate = some limitation of activities; no or minimal medical intervention required. 
• Severe = marked limitation of activities; medical intervention required, possible 
including hospitalization. 
Serious adverse events will be collected for the duration of the study.  All AEs will be monitored 
until resolution or, if the AE is determined to be chronic, until stable.  If an AE remains 
unresolved at the conclusion of the study, a clinical assessment will be made by the investigator 
and medical monitor to determine whether continued follow-up of the AE is warranted. 
Serious Adverse Events 
Serious AEs and AEs listed in the drug investigator brochure will be considered expected events.  
See the Investigator Drug Brochure for additional details of drug expected AEs. 
The relationship of the study treatment to an AE will be determined by the investigator based on 
the following definitions: 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 15 
 
• Not related 
The subject was not exposed to drug, or another cause is obvious. 
• Probably not related 
The AE is more likely explained by another cause, and the time of occurrence of the AE 
is not reasonably related to drug administration. 
• Possibly related 
The drug administration and the AE occurrence were reasonably related in time, and the 
AE is explained equally well by causes other than drug; or drug administration and the 
AE were not reasonably related in time, but the AE is not obviously a result of other 
causes. 
• Probably related 
The drug administration and the AE occurrence were reasonably related in time, and the 
AE is more likely explained by drug exposure than by other mechanisms. 
An SAE is defined as any untoward medical occurrence that: 
• Results in death. 
• Is life threatening (i.e., the subject was, in the opinion of the investigator, at immediate 
risk of death from the event as it occurred). 
• Requires or prolongs hospitalization. 
• Results in persistent or significant disability or incapacity (i.e., the event causes a 
substantial disruption of a person’s ability to conduct normal life functions). 
• Is a congenital anomaly or birth defect in the offspring of the treated subject. 
• Is an important and significant medical event that, based upon appropriate medical 
judgment, may jeopardize the subject or may require medical or surgical intervention to 
prevent one of the other outcomes defining SAE. 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 16 
 
Safety Reporting 
The study drug, benralizumab, is an off-label indication for subjects recruited for this study. The 
Principal Investigator will therefore submit expedited reports, as indicated/necessary for 
reporting of serious adverse drug reactions, by fax, directly to Health Canada Biologics and 
Genetic Therapies Directorate.  
Adverse drug reactions that are both serious and unexpected are subject to expedited reporting to 
Health Canada. Expedited reporting of reactions which are serious but expected is not required. 
Expedited reporting is not required for serious events from clinical investigations that are 
considered unrelated to the study product, whether or not the event is expected.  
In accordance with Health Canada requirements, an Adverse Drug Reaction Report will be filed 
in the cases  
• where the adverse drug reaction is neither fatal nor life-threatening, within 15 days after 
becoming aware of the information;  
• where adverse drug reactions is fatal or life-threatening, immediately where possible 
and, in any event, within 7 days after becoming aware of the information;  
• within 8 days after having informed Health Canada of the adverse drug reactions, submit 
as complete as possible, a report which includes an assessment of the importance and 
implication of any findings 
 All safety reports submitted to Health Canada will also be submitted to AstraZeneca at the 
following address: AEMailboxClinicalTrialTCS@astrazeneca.com. 
Procedures 
Skin Prick Test 
A skin prick test will be used to determine the allergen(s) to which each subject is sensitized. 
Standard allergen extracts will include ragweed, trees, grass, dog, cat, horse, dust mites 
(Dermatophagoides farinae and D. pteronyssinus), Alternaria, and Aspergillus. Extracts will be 
applied to the back then pricking the skin to allow exposure, and then evaluating the local 
reaction in the skin.    A positive control (1 mg/mL histamine) and a negative control (diluent) 
are applied to the skin.  If an allergen provokes an allergic reaction, a raised itchy bump (wheal) 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 17 
 
develops.  The size of the wheal (the raised area, not the redness) will be measured and recorded 
with a ruler in millimeters in the horizontal and vertical directions, perpendicular to each other 
after approximately 15 minutes.  The size of the wheal for each antigen will be recorded on the 
Skin Test Form, along with any observed adverse reaction or event and any actions taken. 
A reaction greater than 2  2 mm will be regarded as positive, provided that the positive and 
negative controls are appropriately positive (histamine) and negative (diluent), respectively.  The 
investigator is to choose an allergen for injection on the basis of the skin response. The 
investigator may choose to perform a RAST test to assist with selection of an appropriate 
allergen.  This procedure will be completed in accordance with the allergen skin testing using the 
epicutaneous method SOP at McMaster University (Hamilton, Ontario, Canada).   
Allergen extracts manufactured following GMP guidelines, will be selected, prepared by staff 
and administered to the subjects by injection in accordance with procedures approved by Health 
Canada.  
Intradermal Allergen Challenge 
The allergen extract selected for intradermal testing will be determined by the results of the skin 
prick test, being the allergen that gives the largest skin wheal.  The selected allergen will be 
injected in a volume of 100 μL intradermally in two adjacent and standardized locations on the 
subject’s back. A saline control will also be injected in a volume of 100 μL intradermally in one 
location of the subject’s back. At 24 hours after challenge, the size of the wheal and flare will be 
measured, and a punch biopsy will be taken from the centre of the sites (2 allergen, 1 diluent) 
plus an adjacent unchallenged/unaffected site.  
Skin Sampling 
Punch biopsies will be obtained from the site of the intradermal allergen (A) and saline (S) 
challenges and an unaffected site (U) adjacent to intradermal challenges using a sterile 4 mm 
skin punch by applying and twisting until the blade of the skin punch has pierced the skin. The 
biopsy will be removed using sterile forceps and a scalpel. These samples will be processed for 
histologic examination of inflammatory cells, including eosinophils, mast cells and basophils.  
A skin lesion (L) will be sampled by excising not more than 1 cm x 3 cm using a sterile scalpel. 
These skin biopsies will be analyzed for inflammatory cells including eosinophils, eosinophil 
progenitors, basophils and mast cells. If the lesion is too small to obtain sufficient cell numbers 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 18 
 
for flow cytometry, only a punch biopsy will be obtained for microscopy. A second skin lesion 
on the contralateral side will be identified for observation throughout the study (measure size, 
photograph, conduct EASI assessment at each visit). 
          
                              
Figure 2 – Site of skin biopsies 
 
Before a biopsy is taken, the skin is thoroughly cleaned and local anesthetic (2% lidocaine) is 
injected to numb the skin. The site of skin biopsies and excision will be sutured and covered with 
a sterile bandage. Subjects will be instructed how to keep the site clean, and sutures will be 
removed at the next study visit. 
Blood Sampling 
At visit 1 (D-1, screening) and visit 7 (D140) blood will be collected for safety labs including 
complete blood count, coagulation, and chemistry including alanine aminotransferase and 
aspartate aminotransferase. At visit 1 blood will also be collected for virology (hepatitis B and C, 
and HIV). Incidental findings would be given the appropriate medical follow up. Women will 
have blood drawn for pregnancy testing or FSH to confirm a woman is post-menopausal. At 
visits 2 (D0) and 6 (D65), 30 mL of blood will be drawn from a vein in the arm using aseptic 
techniques. The blood will be used to measure circulating levels of inflammatory cells, including 
eosinophils, basophils and eosinophil/basophil progenitors. Those performing patient and 
laboratory assessments will remain blinded to the results of the blood cell counts. 
Urine Sampling 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 19 
 
At visit 1 (screening) and visit 8 (follow up) urine will be collected for safety urinalysis. After 
enrolment, urine will be collected from women at visits 2, 3 and 4 before dosing for urine 
pregnancy testing. 
Eczema Area and Severity Index 
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity 
and extent of atopic dermatitis. It is a composite index with scores ranging from 0 to 72. Four 
atopic dermatitis disease characteristics (erythema, thickness [induration, papulation, edema], 
scratching [excoriation], and lichenification) will each be assessed for severity by the 
investigator or designee on a scale of “0” (absent) through “3” (severe). In addition, the area of 
AD involvement will be assessed as a percentage by body area of head, trunk, upper limbs, and 
lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 
(1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 
100%). 
 
Statistical methods 
Using data from a study with the same model (intradermal allergen challenge) in the same 
patient population (moderate-to-severe atopic dermatitis), the sample size requirement was 
determined using data collected from 7 subjects undergoing identical challenge protocols in our 
laboratory in an ongoing study of the protective effects of prednisone treatment. In the 4 
prednisone-treated subjects the mean increase in skin eosinophils during the screening portion of 
the study was 59.8 (42.9) [cells/mm2;M(SD)]. This was reduced to 16.25 (20.6) during the 
prednisone treatment period. The mean % reduction in the delta between the screening and 
prednisone challenges was 80.4 (41.5). To calculate the sample size for the current study, we 
have assumed that treatment with benralizumab will yield a similar protective effect as 
prednisone, and that there will be a similar between subject variability in this protective effect. 
We also assumed that there will be no protective effect in the placebo arm, but that the variability 
in that arm will be similar to that seen in the treatment arm. Thus, using projected mean % 
reduction in the delta eosinophils of 80 in the prednisone arm, 0 in the placebo arm with a SD of 
40 in both of those arms, a sample size of 6 would be needed to demonstrate statistical difference 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 20 
 
using an independent Student t-test. We have chosen to put 10 subjects into each arm to allow for 
subject drop out and also to give increased power for secondary mechanism based investigations. 
 
The primary analysis will be on the % reduction of the allergen induced increase in tissue 
eosinophils. The allergen induced increase in tissue eosinophils will be calculated by subtracting 
the cell count made with saline from the count made with allergen 24h post challenge. This will 
be performed during the screening phase (Day 0) and the treatment phase (Day 65) of the study. 
The percent reduction will be calculated by expressing this increase in the treatment phase as a 
percentage of that in the screening phase. The percent increases during the placebo and active 
treatment arms of the study will be compared using an independent Student t-test. 
Statistical significance will be set at p<0.05.  
Ethics 
Research Ethics Board 
The Principal Investigator (PI) will provide the Research Ethics Board (REB) with all 
appropriate material, including the informed consent document.  The study will not be started 
until appropriate REB approval of the protocol and the informed consent document is obtained.  
Appropriate reports on the progress of the study will be made to the REB by the Principal 
Investigator. 
Ethical Conduct of the Study 
This study will be conducted in accordance with the protocol, Good Clinical Practice (GCP) 
according to International Conference on Harmonization (ICH) guidelines, and regulatory 
requirements for the participating institution.  The study will be conducted by scientifically 
qualified persons and all medical procedures will be performed by a qualified medically trained 
physician.  
Subject Information and Consent 
All subjects will provide informed signed consent.  Before entering subjects into the study, a 
copy of the REB-approved IC will be reviewed with the potential participant, and signed and 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 21 
 
dated.  The investigator will provide a copy of the signed informed consent form to each subject 
and will maintain the original document in the subject’s study file.   
Study Feasibility 
Clinical trial experience 
The laboratory at McMaster University has a dedicated research staff with experience conducting 
phase II clinical trials under the supervision of Dr. Gauvreau. Furthermore, Dr. Gauvreau is 
experienced with Health Canada submissions and reporting, and has published widely on the 
effect of investigational medications in a model of allergy (Gauvreau 2014, 2015, 2016). 
Patient recruitment  
The atopic dermatitis patient population is in need of an effective therapeutic for management of 
their disease, and these patients are readily accessible from Dr. Lima’s outpatient dermatology 
clinic. Dr. Lima manages over 100 patients with atopic dermatitis who are eager to test a new 
medication for control of their disease. Based on routine clinical patch testing, we anticipate the 
majority of patients with moderate to severe atopic dermatitis will develop late cutaneous 
responses to intradermal allergen challenge, and will develop elevated levels of eosinophils and 
basophils following intradermal allergen challenge (Macfarlane 1999). We do not anticipate any 
issues with recruitment or eligibility.  
 
Outcome measurements  
Dr. Sehmi and Dr. Gauvreau have published widely on mechanisms of allergic inflammation, 
using allergen-challenge models to evaluate drug efficacy and mechanisms of disease in patients 
with allergic asthma (Gauvreau 2014, 2015, 2016, Salter 2016, Smith 2015, 2016). Together 
with Medimmune, Dr. Sehmi and Gauvreau have validated a flow cytometry panel for measuring 
basophils, ILC2s, CD4+ T cells and eosinophil progenitor cells to examine the effects 
benralizumab in subjects with allergic asthma in our laboratory (D3250C00040 - ARIA study). 
This same staining panel has been optimized for measurement of these cells in skin of patients 
with atopic dermatitis and pilot data shows positive detection of all cell types of interest. We 
have recruited a research pathologist to conduct all tissue staining and assessments for the 
proposed study (and ARIA).

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 22 
 
Study Schematic 
  
Study Procedures 
Visit 1 
Day -1 
Visit 2 
Day 0 
Visit 2b 
Day 14 
Visit 3 
Day 28 
Visit 4 
Day 56 
Visit 5 
Day 64 
Visit 6 
Day 65 
Visit 7 
Day 140 
Physical Exam/Medical History 
x 
 
Vital Signs 
x 
x 
 
x 
x 
x 
x 
x 
Examination of Skin  
Examination of contralateral lesion 
x 
 
x 
 
x 
x 
x 
 
x 
 
Skin Prick Test 
x 
 
 
 
 
x 
 
 
Patient Questionnaires: 
EASI, IGA, SCORAD, DLQI, 
POEM, PGAD 
 
x 
 
 
x 
x 
x 
 
x 
 
Blood Sample 
Safety 
Efficacy 
x 
x 
 
 
x 
x 
Urine Sample 
Safety 
Pregnancy 
x 
 
x* 
 
x* 
x* 
 
 
x 
 
Intradermal challenges 
x 
 
x 
Skin biopsies 
   From intradermal challenges 
   From lesion 
x 
x 
 
x 
x 
Drug administration 
x 
 
x 
x 
 
 
 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 23 
 
References 
 
Alexander C, Ying S, B Kay A, Larché M. Fel d 1-derived T cell peptide therapy induces 
recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-
induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005 Jan;35(1):52-8. 
 
Beiber, T. (2008). Atopic Dermatitis. The New England Journal of Medicine, 358, 1483–94.  
Blanchard C, Rothenberg ME. Biology of the Eosinophil. In Adv Immunol. 2009; 101: 81–121. 
Bonefeld CM, Geisler C. The role of innate lymphoid cells in healthy and inflamed skin. 
Immunol Lett. 2016 Jan 18. [Epub ahead of print] 
 
Gauvreau GM, O'Byrne PM, Boulet L-P, Wang D, Cockcroft DW, Bigler J, Fitzgerald JM,  
Boedigheimer M, Davis BE, Dias C, Gorski K, Smith L, Bautista E, Comeau MR, Leigh R, 
Parnes JR. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J 
Med. 2014 May 29;370(22):2102-10. 
 
Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, 
Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, 
Matthews JG, O'Byrne PM. Targeting membrane-expressed IgE B cell receptor with an antibody 
to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014 Jul 2;6(243):243ra85 
 
Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Killian KJ, Davis BE, Deschesnes F, 
Watson RM, Swystun V, Mårdh CK, Wessman P, Jorup C, Aurivillius M, O'Byrne PM. A 
Nonsteroidal Glucocorticoid Receptor Agonist Inhibits Allergen-induced Late Asthmatic 
Responses. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. 
 
Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald 
JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun 
V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, 
O'Byrne PM. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab 
and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 
Published online April 2016  
 
Kabashima, K. (2013). New concept of the pathogenesis of atopic dermatitis: Interplay among 
the barrier, allergy, and pruritus as a trinity. Journal of Dermatological Science, 70(1), 3–11. 
 
Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, Hepworth MR, Van 
Voorhees AS, Comeau MR, Artis D. TSLP elicits IL-33-independent innate lymphoid cell 
responses to promote skin inflammation. Sci Transl Med. 2013 Jan 30;5(170). 
 
Peng, W., & Novak, N. (2015). Pathogenesis of atopic dermatitis. Clinical and Experimental 
Allergy, 45(3), 566–574. 

NCT03563066 
 
McMaster University 
Version 8.1 – 27MAY2019 
 
Page 24 
 
 
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. a. (2004). New 
insights into atopic dermatitis. Journal of Clinical Investigation, 113(5), 651–657.  
 
Macfarlane AJ, Kon OM, Smith SJ, Zeibecouglour K, Khan N, Barata LT, McEuen AR, Buckley 
MG, Walls AF, Meng Q, Humbert M, Barnes NC, Robinson DS, Ying S, Kay AB. Basophils, 
eosinophils and mast cells in atopic and nonatopic asthma and in late-phase reactions in the lung 
and skin. J Allergy Clin Immunol 1999; 99-107. 
 
Salter BM, Nusca G, Tworek D, Oliveria JP, Smith SG, Watson RM, Scime T, Obminski C, 
Sehmi R, Gauvreau GM. Expression of activation markers in circulating basophils and the 
relationship to allergen-induced bronchoconstriction in subjects with mild allergic asthma. J 
Allergy Clin Immunol. 2016 Mar;137(3):936-938. 
 
Sehmi, R. and J. Denburg 2000. Differentiation of human eosinophils: role in allergic 
inflammation. In G.Marone, editor Human Eosinophils: Biological and Clinical Aspects,2 
volume 76 ed. Karger, Basel. 29-44. 
 
Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, 
Martin JG, Nair P. Role of local eosinophilopoietic processes in the development of airway  
eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016 Jun;46(6):793-802. 
 
Smith SG, Gugilla A, Mukherjee M, Merim K, Irshad A, Tang W, Kinoshita T, Watson B, 
Oliveria JP, Comeau M, O'Byrne PM, Gauvreau GM, Sehmi R. Thymic stromal lymphopoietin 
and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. 
J Allergy Clin Immunol. 2015 Jun;135(6):1594-602. 
 
Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, Gauvreau GM, Boulet 
LP, Lemiere C, Martin J, Nair P, Sehmi R. Increased numbers of activated group 2 innate 
lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J 
Allergy Clin Immunol. 2016 Jan;137(1):75-86. 
 
Wardlaw, A. J. 1999. Molecular basis of selective eosinophil trafficking in asthma: a multi-step 
paradigm. JACI 104:917-926. 
 
Williams, H., & Flohr, C. (2006). How epidemiology has challenged 3 prevailing concepts about 
atopic dermatitis. Journal of Allergy and Clinical Immunology, 118(1), 209–213.